SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Haemonetics Corporation (HAE) trades at a trailing P/E of 15.6, forward P/E of 12.2. Trailing earnings yield is 6.39%, forward earnings yield 8.18%. PEG 0.35 (Peter Lynch undervalued ≤1.0). Graham Number is $40.54.
Criteria proven by this page:
- VALUE (70/100, Pass) — P/E is below market average (15.6); PEG ≤ 1.0 — Peter Lynch undervalued (0.35); analyst target implies upside (+43.2%); earnings yield beats bond yields (6.39%).
- Forward P/E 12.2 (down from trailing 15.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.35 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 6.39% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 8.18% as earnings recover.
- Analyst consensus target $86.60 (+43.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 77/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
70/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HAE
Valuation Multiples
P/E (TTM)15.6
Forward P/E12.2
PEG Ratio0.35
Forward PEG0.25
P/B Ratio3.01
P/S Ratio2.08
EV/EBITDA9.6
Per Share Data
EPS (TTM)$3.75
Forward EPS (Est.)$4.95
Book Value / Share$19.48
Revenue / Share$28.17
FCF / Share$6.58
Yields & Fair Value
Earnings Yield6.39%
Forward Earnings Yield8.18%
Dividend Yield0.00%
Graham Number$40.54
SharesGrow IV$127.27 (+110.4%)
Analyst Target$86.60 (+43.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-32.0 |
0.07 |
2.47 |
1.96 |
- |
| 2017 |
-79.5 |
1.49 |
2.83 |
2.36 |
- |
| 2018 |
84.7 |
-0.32 |
5.13 |
4.27 |
- |
| 2019 |
84.1 |
3.44 |
6.93 |
4.78 |
- |
| 2020 |
66.0 |
1.61 |
8.60 |
5.11 |
- |
| 2021 |
70.8 |
17.82 |
7.69 |
6.46 |
- |
| 2022 |
74.4 |
-1.62 |
4.31 |
3.25 |
- |
| 2023 |
36.4 |
0.22 |
5.14 |
3.60 |
- |
| 2024 |
36.6 |
16.60 |
4.48 |
3.28 |
- |
| 2025 |
19.0 |
0.44 |
3.87 |
2.34 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$1.48 |
$988.48M |
$76.53M |
7.7% |
| 2021 |
$1.55 |
$870.46M |
$79.47M |
9.1% |
| 2021 |
$1.55 |
$870.46M |
$79.47M |
9.1% |
| 2022 |
$0.84 |
$993.2M |
$43.38M |
4.4% |
| 2022 |
$0.84 |
$993.2M |
$43.38M |
4.4% |
| 2023 |
$2.24 |
$1.17B |
$115.4M |
9.9% |
| 2023 |
$2.24 |
$1.17B |
$115.4M |
9.9% |
| 2024 |
$2.29 |
$1.31B |
$117.56M |
9% |
| 2024 |
$2.29 |
$1.31B |
$117.56M |
9% |
| 2025 |
$3.31 |
$1.36B |
$167.68M |
12.3% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$4.95 |
$4.93 – $4.98 |
$1.33B |
$1.32B – $1.34B |
8 |
| 2027 |
$5.32 |
$5.15 – $5.49 |
$1.39B |
$1.37B – $1.41B |
8 |
| 2028 |
$5.93 |
$5.52 – $6.17 |
$1.49B |
$1.49B – $1.49B |
5 |
| 2029 |
$6.90 |
$6.76 – $7.02 |
$1.64B |
$1.61B – $1.66B |
3 |
| 2030 |
$7.66 |
$7.50 – $7.80 |
$1.76B |
$1.73B – $1.78B |
3 |
